Alex­ion adds a failed piv­otal Soliris tri­al to an air of cri­sis. The per­fect time to talk buy­out

With its ex­ec­u­tive suite in tur­moil and the com­pa­ny in cri­sis over an un­ex­plained fraud probe, Alex­ion $ALXN re­port­ed to­day that its Phase II/III reg­is­tra­tion study for Soliris for a se­ri­ous com­pli­ca­tion linked to or­gan trans­plants has failed.

In­ves­ti­ga­tors were hop­ing to make a case for the ex­pand­ed use of Soliris in treat­ing de­layed graft func­tion (DGF) af­ter kid­ney trans­plan­ta­tion in adult re­cip­i­ents of a de­ceased donor kid­ney has failed. But in look­ing at a pri­ma­ry end­point that eyed the drug’s im­pact on the need for dial­y­sis as well as death, graft loss, and loss to fol­low-up, in­clud­ing dis­con­tin­u­a­tion, the drug flopped against the place­bo arm.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.